This Article Full Text (PDF) Correction (v53,p6079) Correction (v53,p6079) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ganapathi, R. Articles by Ford, J. Search for Related Content PubMed PubMed Citation Articles by Ganapathi, R. Articles by Ford, J.

Selective Enhancement of Vincristine Cytotoxicity in Multidrug-resistant Tumor Cells by Dilantin (Phenytoin)¹

Departments of Cancer Biology [R. G., D. G., J. F.] and Radiation Therapy [A. H.], Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195

Tumor cell resistance to chemotherapeutic agents of diverse structure and mechanism of action is thought to be due to efflux of drug by P-glycoprotein, which is overexpressed in tumor cells with the multidrug-resistant phenotype. Agents generally associated with the multidrug-resistant phenotype include inhibitors of topoisomerase II, e.g., doxorubicin, etoposide, and the microtubule poisons such as vinblastine, vincristine (VCR), and taxol. The antiepileptic drug phenytoin (DPH), an inhibitor of tubulin polymerization, potentiates (P < 0.05) the cytotoxicity of the chemotherapeutically useful microtubule poison VCR in tumor cells with the wildtype or multidrug-resistant phenotype. Among agents associated with the multidrug-resistant phenotype, the modulation of cytotoxicity by DPH was selectively effective with the microtubule poison VCR but not the topoisomerase II inhibitor doxorubicin. The potentiation of vincristine cytotoxicity by DPH was not due to binding to P-glycoprotein or by increasing VCR accumulation. We thus propose a novel mechanism for the modulation of resistance based on evidence that DPH at noncytotoxic concentrations can selectively enhance the cytotoxic potential of vincristine without interfering with P-glycoprotein function. Thus, studies with phenytoin could assist in characterizing other molecular determinants of multidrug resistance and the design of trials to modulate drug efficacy.

¹ Supported by Public Health Service Grant CA35531 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at the Research Institute, Room M3-30, 9500 Euclid Avenue, Cleveland Clinic Foundation, Cleveland, OH 44195.

Received 4/29/93. Accepted 6/14/93.

This article has been cited by other articles:

				S. Lobert, J. W. Ingram, and J. J. Correia Additivity of Dilantin and Vinblastine Inhibitory Effects on Microtubule Assembly Cancer Res., October 1, 1999; 59(19): 4816 - 4822. [Abstract] [Full Text] [PDF]